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Abstract
Background: Healthcare utilization data are increasingly used for chronic disease surveillance. Nevertheless,
no standard criteria for estimating prevalence of high-impact diseases, such as chronic obstructive pulmonary
disease (COPD) and asthma, are available. In this study an algorithm for recognizing COPD/asthma cases
from HCU data is developed and implemented in the HCU databases of the Italian Lombardy Region
(about 10 million residents). The impact of diagnostic misclassification for reliably estimating prevalence
was also assessed.
Methods: Disease-specificdrug codes, hospital discharges together with co-payment exemptions when
available, and a combination of them according with patient’s age, were used to create the proposed
algorithm. Identified cases were considered for prevalence estimation. An external validation study was
also performed in order to evaluate systematic uncertainty of prevalence estimates.
Results: Raw prevalence of COPD and asthma in 2010 was 3.6 and 3.3% respectively. According to external
validation, sensitivity values were 53% for COPD and 39% for asthma. Adjusted prevalence estimates were
respectively 6.8 and 8.5% for COPD (among person aged 40 years or older) and asthma (among person aged
40 years or younger).
Conclusions: COPD and asthma prevalence may be estimated from HCU data, albeit with high systematic
uncertainty. Validation is recommended in this setting.
Keywords: Prevalence, Asthma, Chronic obstructive pulmonary disease, Healthcare utilization database,
Algorithms
Background
Chronic obstructive pulmonary disease (COPD) and
asthma are two of the most common chronic respiratory
diseases (CRDs). CRDs have a large impact on public
health due to both their high prevalence and related
morbidity and mortality and their substantial socio-
economic costs [1–3].
Assessing the burden of CRDs through valid and up-
dated estimates of their prevalence, may help healthcare
decision makers in guiding public health policy, even
though such estimates are not easy to obtain.
Since patients affected by CRDs plausibly make use of
healthcare services during the course of their disease,
healthcare utilization (HCU) databases are frequently
considered as useful data sources to capture CRD cases
and estimate their prevalence in large unselected popula-
tions [4–7]. To this aim, investigators typically use ad-hoc
algorithms based on the use of healthcare services, such
as drug dispensations or hospital admissions. Clearly, such
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algorithms may be characterized by different operating
characteristics, but validated standards are currently un-
available in this setting.
To assess the reliability of the algorithms in capturing
patients affected by COPD and asthma, we conducted a
cross-sectional study based on the HCU databases of the
Italian Lombardy Region. In this study, we i) employed
several algorithms to detect COPD and asthma cases from
HCU data, ii) assessed the agreement between them, iii)
evaluated the impact of misclassification on the prevalence
estimates of COPD and asthma and iv) compared our
prevalence with those available from the scientific literature.
Methods
Data source
The data used for this study were retrieved from the
HCU databases of Lombardy, a Region of Italy account-
ing for about 16% (almost 10,000,000) of the national
population. In Italy, the entire population benefits from
healthcare assistance provided by the National Health
Service (NHS), which in Lombardy has been associated
since 1997 with an automated system of databases.
Among others, these include: 1) an archive of NHS benefi-
ciaries (practically the whole resident population), report-
ing demographic and administrative data; 2) a hospital
discharge database, reporting all discharge diagnoses re-
leased from public or private hospitals; 3) an outpatient
drug prescriptions database, reporting all dispensations of
drugs reimbursable by the NHS; and 4) an archive of co-
payment exemptions reporting information on all benefi-
ciaries of co-payment exemptions granted for selected
chronic diseases. For each patient, we linked these data-
bases via a single anonymous identification code in full
preservation of individuals’ privacy [8].
Algorithms for case detection and prevalence estimation
The target population consisted in all beneficiaries of
NHS assistance, residing in Lombardy Region in 2010.
Three algorithms were considered for detecting pa-
tients suffering of COPD and asthma from HCU data-
bases. The first one, denoted as reference algorithm, was
based on expert opinions of the scientific board of
CRACK-CRD program, composed by general practi-
tioner, lung specialists and epidemiologists. This algo-
rithm was obtained combining age (<40 year for asthma
and ≥40 years for BPCO) and use of healthcare services
considering the hospital discharges, drug dispensations
and co-payment exemptions (asthma only) recorded in
the databases during 2010 for capturing the target dis-
eases (Table 1).
Starting from the criteria proposed by Anecchino et al.
[9] for COPD, and Bianchi et al. [10] for asthma, two
comparison algorithms were also implemented taking
into account for case definition age (<40 year for asthma
and ≥40 years for BPCO) and drug dispensations only.
The drugs considered in these algorithms are those in-
cluded in the reference algorithm. In particular, patients
were identified as cases if they received at least one
(permissive algorithm), or ≥2 dispensations (restrictive
algorithm) of the considered medicaments during 2010
(Table 2).
The specific codes used to identify the asthma and
COPD cases in terms of drug prescriptions (ATC codes)
[9, 10], diagnosis at discharge (ICD-9 CM codes) [11] for
asthma and COPD and exemptions for asthma [12] for
the three algorithms are listed in the Additional file 1:
Table S1.
Cases detected from each of these algorithms follow-
ing the criteria reported in Tables 1 and 2 were consid-
ered to estimate the raw prevalence of asthma and
Table 1 Reference algorithm used to capture COPD and asthma cases among the beneficiaries of the Regional Health Service.
Lombardy, Italy
COPD Asthma
≥40 years of age
And at least one of the following criteriaa:
≥1 hospitalizations for COPD
≥2 prescr/year of tiotropium or LABAs (in monotherapy),
LABA/ICS in fixed combinations, SABAs
≥2 prescr/year of ICS in addition to ≥2 prescr/year of
ipratropium or oxitropium
≥2 prescr/year of theophylline and ≥2 prescr/year of
any of the following drugs:beta-agonists, ipratropium,
oxitropium, inhaled corticosteroids
<40 years of age
And at least one of the following criteriaa:
Benefitted of exemption for asthma
≥1 hospitalizations for asthma
≥2 prescr/year of any of the following drugs: anti-leukotrienes, chromones,
≥2 prescr/year of any of the following drugs: SABAs, LABA/ICS fixed
combinations (only 0–19 age)
≥2 prescr/year of ICS in addition to ≥1 prescr/year of SABAs
≥2 prescr/year of ICS in addition to ≥2 prescr/year of ipratropium, oxitropium or
theophylline (only 0–19 age)
≥1 prescr/year of antibiotics (ATC: J01; only 20–39 age) in addition to at least
one of the following criteria:
≥2 prescr/year of theophylline and ≥2 prescr/year of any of the following drugs:
beta-agonists, ipratropium, oxitropium, inhaled corticosteroids
≥2 prescr/year of SABAs or LABA/ICS fixed combinations
≥2 prescr/year. of ICS in addition to ≥2 prescr/year of ipratropium or oxitropium
To be recognized as affected by COPD/asthma, an individual must satisfy at least one of the listed criteria evaluated in 2010
Abbreviations: prescr/yr. prescription per year
aThe specific ATC, ICD-9 CM and exemption codes used to identify asthma and COPD cases are reported in Additional file 1: Table S1
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COPD considering all beneficiaries of NHS assistance
during 2010 as reference population.
Assessing between algorithms agreement
The between algorithms agreement in detecting patients
suffering of COPD and asthma was measured by means
of Cohen’s Kappa (K) index [13]. Following Landis &
Koch [14], values K ≥0.80 were considered as represent-
ing optimal agreement.
External validation and accounting for misclassification
The algorithms’ validation was performed involving data re-
trieved from a network of about 50 general practitioners
(GPs) from Lombardy Region participating in the network
on voluntary basis. In particular, the GPs identified among
their patients those with a diagnosis of COPD or asthma
based on standard practice criteria including the evaluation
of the manifestation of the disease, patients characteristics
such history of chronic or recurrent cough, sputum, wheez-
ing or shortness of breath or based on the diagnosis of
COPD or asthma made by a lung specialists or other
specialized doctor. The information of these patients were
then, reported to us. Assuming that the GP’s diagnosis were
errors free, the proportion of individuals detected by a given
algorithm as suffering from COPD or asthma among
those reported by GPs defines the sensitivity (SE) of
that algorithm.
The method proposed by Rogan & Gladen [15] was
used to account for diagnostic misclassification. In
particular, assuming 100% specificity, the adjusted
prevalence was calculated by the ratio between raw
prevalence and SE.
Comparison with the literature
We carried out a MEDLINE / GOOGLE SCHOLAR
search of studies published from 2005 to 2013 reporting
prevalence of COPD or asthma in Italy. The studies were
classified according to the data source. In particular, we
included studies based on HCU databases, network of
GPs and population-based survey. The prevalence
reported by each individual study was compared to that
obtained applying our reference algorithm to Lombardy’s
HCU databases considering the same calendar years and
age range of the considered study. Both raw and
adjusted prevalence derived from Lombardy HCU data-
bases were reported.
Statistical analyses were performed using SAS (v9.3;
SAS Institute, Cary, North Carolina, USA).
Results
In 2010 there were 10,172,161 NHS beneficiaries in
Lombardy (43% with age <40 years).
The number COPD and asthma cases detected in this
population varied substantially depending on the consid-
ered algorithm (Table 3).
The majority of patients with asthma were detected by
the reference algorithm through prescriptions (74%) and
exemptions (16%). Only the 1% of cases was identified by
hospitalization only. Even for COPD the largest number
of cases was identified through prescriptions (84%), the
7% by hospitalization only and the 9% using both sources.
Apparently, there were not substantial differences in
terms of prevalence between the reference and restrict-
ive algorithms, in fact the prevalence estimates were
3.3% for asthma considering both algorithms and 3.6 or
Table 2 Comparison algorithms used to capture COPD and asthma cases among the beneficiaries of the Regional Health Service.
Lombardy, Italy
COPD Asthma
Permissive algorithm
≥40 years of age
And at least one of the following criteriaa:
≥1 prescr/year of one of the following drugs:
SABA, SAMA, LAMA, LABA, LABA/ICS, ICS
<40 years of age
And at least one of the following criteriaa:
≥1 prescr/year of one of the following drugs:
SABA, LABA, LABA/ICS, ICS, chromones, anticholinergics, theophylline
≥1 prescr/year of anti-leukotrienes
and ≥1 prescr/year of any other drug for chronic respiratory diseases
≥1 prescr/year of oral steroids
and ≥1 prescr/year of any other drug for chronic respiratory diseases
Restrictive algorithm
≥40 years of age
And at least one of the following criteriaa:
≥2 prescr/year of one of the following drugs:
SABA, SAMA, LAMA, LABA, LABA/ICS, ICS
<40 years of age
And at least one of the following criteriaa:
≥2 prescr/year of one of the following drugs:
SABA, LABA, LABA/ICS, ICS, chromones, anticholinergics, theophylline
≥2 prescr/year of anti-leukotrienes
and ≥2 prescr/year of any other drug for chronic respiratory diseases
≥2 prescr/year of oral steroids and ≥2 prescr/year of any other drug for
chronic respiratory diseases
To be recognized as affected by COPD/asthma, an individual must satisfy at least one of the listed criteria evaluated in 2010
Abbreviations: prescr/year. prescription per year
aThe specific ATC codes used to identify asthma and COPD cases are reported in Additional file 1: Table S1
Biffi et al. BMC Pulmonary Medicine  (2017) 17:20 Page 3 of 8
3.8% for COPD respectively for the reference and restrict-
ive algorithms while the permissive algorithm reports
much higher estimates. Moderate and fair agreement ac-
cording to Landis and Koch scale was observed between
reference and the permissive comparison algorithm re-
spectively for COPD (Kappa index = 0.46) and asthma
(Kappa index = 0.35) suggesting that the two algorithms
often detected different patients. A substantial agreement
was instead observed for the restrictive algorithm for both
the respiratory diseases investigated. Moreover, both refer-
ence and restrictive algorithms detected just over half of
the patients suffering of COPD (being the corresponding
sensitivity estimates 53 and 51%) and almost a third of
those suffering of asthma (being the corresponding sensi-
tivity estimates 39 and 31%). As expected, a higher num-
ber of cases was detected from the permissive algorithm,
but the strong disagreement with the reference one sug-
gests that most of them were false positives or, conversely,
that the reference algorithm is unable to detect all poten-
tial asthma and COPD cases due to its low sensitivity.
In Table 4 are reported the age and gender specific
asthma and COPD distribution and prevalence accord-
ing to the different algorithms implemented.
Prevalence of COPD seems to increase with age in both
males and females according to all algorithms. Regarding
gender differences, considering the reference algorithm,
the prevalence seems higher in females than in males
while no strong differences were observed in the gender-
specific estimates obtained with the other algorithms.
Regarding asthma, the estimates are higher in men than in
women and in particular in the age class 0–19 years.
In Table 5 the prevalence estimates reported from
selected Italian studies are compared [6, 9, 10, 16–24]
with those obtained from our reference algorithm.
Studies based on HCU data generally reported COPD
and asthma prevalence very close to that obtained from
our reference algorithm (raw prevalence). Similar COPD
prevalence was also obtained from the unique study based
on GPs data and our reference algorithm. In all the other
cases (i.e., surveys reporting COPD or asthma prevalence
and GPs-based studies reporting asthma prevalence)
much lower prevalence was obtained from our reference
algorithm respect to the original reporting. As expected,
closest estimates were obtained accounting for diag-
nostic misclassification, although original prevalence
based on surveys almost always showed higher values.
Finally, it should be emphasized that original esti-
mates were more heterogeneous than those based on
our algorithm. In fact, estimates ranged from 2.8 to
7.2% and from 3.6 to 7.2% according to original and
algorithm-based COPD prevalence, and from 3.5 to
10.7% and from 3.3 to 7.9% according to original and
algorithm-based asthma prevalence.
Discussion
An algorithm for detecting patients suffering from
COPD and asthma from HCU databases was applied
to the population of the Italian Region of Lombardy in
the year 2010. We found a prevalence of 3.6 and 3.3%
for COPD and asthma respectively. Our algorithm was
employed to favour the specificity of detection. In
other words, since it is unlikely that an individual who
does not suffer from COPD (or asthma) is hospitalized
with a diagnosis of COPD (or asthma), and/or uses a
medication to treat COPD (or asthma) and/or benefits
of exemption for asthma, the rate of false positives
detected by our algorithm is expected to be close to
zero. It is not surprising that the prevalence estimates
obtained by other algorithms, mainly based on drug
dispensation [9, 10], widely disagree with ours, likely due
to 1) false positive reports (e.g. of patients suffering of
bronchitis and bronchiectasis) and/or 2) too broad drug
categories (e.g. any respiratory medicament) [6, 16, 17].
However, we realized that, despite the high expected
specificity, our algorithm is affected by no optimal
sensitivity, being the latter a very serious weakness
for investigations aimed to measure the burden of
disease. In fact, we found that just over half and one
Table 3 Evaluation of the agreement between reference and comparison algorithms and detection of their sensitivity. Lombardy,
Italy, 2010
Algorithm # patients (prevalence %) Cohen’s Kappa a Sensitivity b
COPD (patients aged 40 years or older)
Reference algorithm c 206,732 (3.6%) - 52.6%
Permissive algorithm d 545,520 (9.4%) 0.46 72.9%
Restrictive algorithm d 217,095 (3.8%) 0.75 51.0%
Asthma (patients aged 40 years or younger)
Reference algorithm c 143,171 (3.3%) - 38.8%
Permissive algorithm d 440,130 (10.1%) 0.35 63.4%
Restrictive algorithm d 142,482 (3.3%) 0.61 30.6%
aAgreement between reference and comparison (permissive and restrictive) algorithms; b Obtained from external validation data; c Please see Table 1 for details
on reference algorithm; d Please see Table 2 for details on permissive and restrictive algorithms
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third of patients suffering from COPD and asthma
were respectively detected from our algorithm, mak-
ing prevalence seriously biased towards underestima-
tion. However, measuring sensitivity of our algorithm
through an external validation, adjusted prevalence of
6.8% (COPD among person aged 40 years or older)
and 8.5% (asthma among person aged 40 years or
younger) were obtained. These figures should be com-
pared with the 8.8% prevalence of COPD in adults
aged ≥40 years and 7.4% prevalence of asthma in per-
sons aged <44 years, reported for the 28 countries of
the European Union around 2010 [25]. The risk of
misdiagnosis of COPD and asthma in general practice
is generally considered to be of some concern [18]
and for this reason GPs’ reports must to be consid-
ered an imperfect gold-standard for validation of our
algorithms. It follows that the prevalence of COPD
and asthma obtained in our study should be consid-
ered biased, even if they were corrected for potential
misclassification of the diagnosis. It should be empha-
sized, however, that our prevalence estimates were
similar to those obtained assuming a sensitivity of
GPs diagnosis of 0.77 and 0.81 for COPD and asthma
respectively (i.e., those found in a recent Multicentric
Italian study [26]) and specificity close to 1 (i.e., with
values of 0.98 and 1.00 for COPD and asthma
respectively).
The raw prevalence estimates showed in the present
study seems to be lower compared to those reported in
other studies regarding the Italian population available
in the scientific literature. Different reasons may explain
these observed differences; first of all, a lack of homo-
geneity in the criteria used to identify COPD and asthma
cases is observed. In fact, every study uses a different
algorithm for case definition characterized by its own
predictive value affecting the number of cases detected
and consequently the prevalence estimates. Secondly,
the sources of data (HCUs, surveys, GPs) used to esti-
mate prevalence in the scientific literature are character-
ized by different level of completeness and information
that may influence the prevalence estimates obtained. In
particular, the surveys can include patients who may
have mild symptoms that do not lead them to seek
medical care and often investigate unspecific symptoms
rather than carefully diagnosed diseases.
It must be mentioned that HCUs are a useful data source
to investigate the prevalence of diseases because they
describe in a very accurate way the real world practice but
Table 4 Age and gender specific asthma and COPD distribution and prevalence according to the different algorithms implemented
Age Males (%) Prevalence % Females (%) Prevalence %
COPD (patients aged 40 years or older)
Reference algorithm 40–59 24,622 (23.1) 1.6 27,082(27.0) 8.3
60–79 59,746 (56.1) 6.0 49,430(49.3) 11.3
80+ 22,120 (20.8) 10.6 23,733(23.7) 11.7
Total 106,488 3.9 100,244 9.9
Permissive algorithm 40–59 90,918 (37.6) 6.0 123,519 (40.7) 8.3
60–79 113,182 (46.8) 11.3 129,519 (42.7) 11.3
80+ 37,803 (15.6) 18.0 50,579 (16.7) 11.7
Total 241,903 8.9 303,617 9.9
Restrictive algorithm 40–59 27,154 (25.4) 1.8 32,538 (29.5) 2.2
60–79 56,286 (52.6) 5.6 52,108 (47.4) 4.6
80+ 23,611 (22.0) 11.3 25,398 (23.1) 5.9
Total 107,051 3.9 110,044 3.6
Asthma (patients aged 40 years or younger)
Reference algorithm 0–19 18,770 (48.6) 1.9 40,489 (38.7) 4.4
20–39 19,844 (51.4) 1.6 64,069 (61.3) 5.3
Total 38,613 1.7 104,558 4.9
Permissive algorithm 0–19 169,642 (73.5) 17.2 132,105 (63.1) 14.3
20–39 61,046 (26.5) 4.9 77,337 (36.9) 6.4
Total 230,688 10.4 209,442 9.9
Restrictive algorithm 0–19 57,395 (71.7) 5.8 38,572 (61.8) 4.2
20–39 22,698 (28.3) 1.8 23,817 (38.2) 2.0
Total 80,093 3.6 62,389 2.9
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on the other hand, they cannot capture patients affected by
COPD or asthma who do not require specific care, not ac-
cess to healthcare [27] or not consult the GPs [28].
Conclusions
In conclusion, our study confirms and adds further
evidence that COPD and asthma should be considered
important public health issues also in Italy since almost
9% of children and young adults and 7% of older adults
is actually affected by asthma or COPD respectively. As
a novel and original message, our study showed that
HCU databases are useful sources for estimating
prevalence of COPD and asthma, provided that vali-
dated algorithms combining the use of several health-
care service are applied for detecting ill patients. This
is of great importance because, given the wide avail-
ability of high quality HCU data, monitoring and
comparing burden of chronic respiratory diseases, as
well as evaluating the impact of public health ser-
vices, is easily accomplished with limited efforts.
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GPs Cazzola, 2011 [18] 2009 ≥15 6.1 1.5 3.8
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